Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Gilead Sciences Inc Stock Research

GILD

73.27USD-0.83(-1.12%)Market Closed
Watchlist

Market Summary

USD73.27-0.83
Market Closed
-1.12%

GILD Alerts

  • 1 major insider sales recently.

GILD Stock Price

GILD RSI Chart

GILD Valuation

Market Cap

92.4B

Price/Earnings (Trailing)

16.85

Price/Sales (Trailing)

3.37

EV/EBITDA

10.07

Price/Free Cashflow

10.35

GILD Price/Sales (Trailing)

GILD Profitability

EBT Margin

26.87%

Return on Equity

26.59%

Return on Assets

9.02%

Free Cashflow Yield

9.66%

GILD Fundamentals

GILD Revenue

Revenue (TTM)

27.4B

Revenue Y/Y

5.42%

Revenue Q/Q

3.89%

GILD Earnings

Earnings (TTM)

5.5B

Earnings Y/Y

-8.65%

Earnings Q/Q

3.47%

Price Action

52 Week Range

62.4888.45
(Low)(High)

Last 7 days

-1.0%

Last 30 days

-3.3%

Last 90 days

-3.4%

Trailing 12 Months

22.3%

GILD Financial Health

Current Ratio

1.28

Debt/Equity

1.19

Debt/Cashflow

0.36

GILD Investor Care

Dividend Yield

3.99%

Dividend/Share (TTM)

2.96

Buy Backs (1Y)

0.72%

Diluted EPS (TTM)

4.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for GILD

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-12
Parsey Merdad
sold
-115,562
76.99
-1,501
chief medical officer
2023-09-10
Patterson Sandra
acquired
-
-
519
svp, controllership
2023-09-10
Parsey Merdad
sold (taxes)
-97,128
76.00
-1,278
chief medical officer
2023-09-10
Mercier Johanna
sold (taxes)
-95,456
76.00
-1,256
chief commercial officer
2023-09-10
O'Day Daniel Patrick
acquired
-
-
7,348
chairman & ceo
2023-09-10
Patterson Sandra
sold (taxes)
-11,324
76.00
-149
svp, controllership
2023-09-10
Dickinson Andrew D
acquired
-
-
2,619
chief financial officer
2023-09-10
Mercier Johanna
acquired
-
-
2,730
chief commercial officer
2023-09-10
O'Day Daniel Patrick
sold (taxes)
-255,816
76.00
-3,366
chairman & ceo
2023-09-10
Parsey Merdad
acquired
-
-
2,779
chief medical officer

1–10 of 50

Which funds bought or sold GILD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-10-02
PARK NATIONAL CORP /OH/
added
22.51
49,240
306,654
0.01%
2023-09-26
M Holdings Securities, Inc.
sold off
-100
-726,000
-
-%
2023-09-26
BROOKFIELD Corp /ON/
reduced
-92.45
-2,694,740
203,234
-%
2023-09-21
Baystate Wealth Management LLC
added
17.83
2,775
32,616
-%
2023-09-21
Jefferies Group LLC
new
-
2,313,740
2,313,740
0.02%
2023-09-20
Mondrian Investment Partners LTD
unchanged
-
-17,853
233,214
-%
2023-09-20
BARCLAYS PLC
added
47.07
137,216,000
511,970,000
0.32%
2023-09-14
IMS Capital Management
unchanged
-
-28,987
378,645
0.21%
2023-09-12
Farther Finance Advisors, LLC
added
3.14
-22,010
503,190
0.11%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
added
13.72
14,280
267,587
0.08%

1–10 of 44

Latest Funds Activity

Are funds buying GILD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own GILD
No. of Funds

Schedule 13G FIlings of Gilead Sciences

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
capital research global investors
4.4%
54,602,952
SC 13G/A
Feb 13, 2023
capital world investors
5.5%
68,900,998
SC 13G
Feb 09, 2023
vanguard group inc
8.93%
112,038,324
SC 13G/A
Jan 31, 2023
blackrock inc.
10.5%
131,555,769
SC 13G/A
Jul 08, 2022
blackrock inc.
10.1%
126,932,693
SC 13G
Feb 11, 2022
capital research global investors
8.5%
107,156,981
SC 13G/A
Feb 10, 2022
vanguard group inc
8.43%
105,803,799
SC 13G/A
Feb 01, 2022
blackrock inc.
9.5%
118,961,206
SC 13G/A
Feb 16, 2021
capital research global investors
9.7%
121,672,399
SC 13G/A
Feb 16, 2021
capital research global investors
9.7%
121,672,399
SC 13G/A

Recent SEC filings of Gilead Sciences

View All Filings
Date Filed Form Type Document
Sep 29, 2023
4
Insider Trading
Sep 14, 2023
8-K
Current Report
Sep 13, 2023
4
Insider Trading
Sep 12, 2023
144
Notice of Insider Sale Intent
Sep 11, 2023
4
Insider Trading
Sep 11, 2023
4
Insider Trading
Sep 11, 2023
4
Insider Trading
Sep 11, 2023
4
Insider Trading
Sep 11, 2023
4
Insider Trading
Sep 11, 2023
424B5
Prospectus Filed

GILD Fair Value

Loading...

Peers (Alternatives to Gilead Sciences)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
142.4B
26.6B
3.74% 20.01%
17.85
5.36
0.75% 21.34%
92.4B
27.4B
-3.33% 22.27%
16.85
3.37
-0.48% 32.56%
39.4B
10.7B
-8.22% -12.63%
32.61
3.69
-53.67% -91.41%
36.6B
10.0B
-5.36% -5.30%
13.73
3.67
-6.23% 29.40%
MID-CAP
10.9B
1.7B
1.05% 5.25%
61.85
6.52
29.01% 1345.90%
4.1B
-
-16.91% 155.63%
-7.02
48.33
54.84% -12.96%
2.7B
-
-15.10% -35.52%
-21.18
37.44
122.90% 54.78%
1.7B
80.2M
-8.35% -54.87%
-5.12
20.91
42.17% -39.82%
SMALL-CAP
1.3B
121.2M
-18.44% -33.91%
-4.48
10.62
-70.36% -531.73%
931.2M
15.3M
-19.93% -8.57%
-5.13
60.82
1090.59% -36.57%
668.6M
1.6B
-13.64% -61.04%
-1.14
0.42
23.74% 60.24%
189.2M
-
-31.67% -91.43%
-0.89
1.38
116.83% 16.61%
113.0M
2.1M
-10.53% -65.89%
-1.12
55
487.70% -8.66%
104.6M
-
-38.94% -87.76%
-0.53
0.43
113.96% -15.19%
6.3M
-
5.48% -92.77%
-0.08
3.21
- -129.46%

Gilead Sciences News

MarketWatch
Gilead Sciences Inc. stock falls Tuesday, still outperforms market.
MarketWatch,
118 minutes ago
StockNews.com
Marketscreener.com

Returns for GILD

Cumulative Returns on GILD

4.4%


10-Year Cumulative Returns

2.7%


7-Year Cumulative Returns

2.4%


5-Year Cumulative Returns

9.9%


3-Year Cumulative Returns

Risks for GILD

What is the probability of a big loss on GILD?

41.9%


Probability that Gilead Sciences stock will be more than 20% underwater in next one year

0%


Probability that Gilead Sciences stock will be more than 30% underwater in next one year.

0%


Probability that Gilead Sciences stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does GILD drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Gilead Sciences was unfortunately bought at previous high price.

Drawdowns

Financials for Gilead Sciences

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue1.3%27,38227,04327,28127,13627,51527,47227,30527,48226,63825,56424,68923,14722,17422,71622,44922,36522,35722,32022,12722,28123,197
Costs and Expenses3.9%18,90818,20519,95121,13320,50720,24717,38715,85316,85021,00520,61820,63423,13518,26418,16218,02713,92314,03613,92712,93412,661
  S&GA Expenses8.3%6,4015,9095,6735,3035,2805,2745,2465,3265,2425,1305,1514,6254,5714,4274,3814,3084,2044,0894,0564,1774,108
  R&D Expenses--------------9,1509,1069,1575,1065,1385,0183,2903,140
EBITDA-100.0%-8,5307,0725,8196,8487,1759,60810,6818,0452,9302,6532,7164045,7956,155------
EBITDA Margin-100.0%-0.32*0.26*0.21*0.25*0.26*0.35*0.39*0.30*0.11*0.11*0.12*0.02*0.26*0.27*------
Interest Expenses-1.3%9159279359479689821,0011,0301,0161,0009849609749829951,0091,0231,0411,0771,1171,144
Earnings Before Taxes1.2%7,3517,2665,8144,5425,5485,8628,2789,3336,7201,9301,6691,756-5704,8135,1604,2758,4408,1167,7998,9099,916
EBT Margin-100.0%-0.27*0.21*0.17*0.20*0.21*0.30*0.34*0.25*0.08*0.07*0.08*-0.03*0.21*0.23*------
Net Income-1.8%5,4845,5834,5923,3344,1374,5156,2257,3945,1623011231,268-2574,9625,3862,6935,9555,8925,4551,5872,208
Net Income Margin-100.0%-0.21*0.17*0.12*0.15*0.16*0.23*0.27*0.19*0.01*0.00*0.05*-0.01*0.22*0.24*------
Free Cashflow-100.0%-8,3868,3449,0079,4159,95310,8059,4918,4728,6987,5188,1608,7648,2448,319------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets0.7%62,33761,87663,17162,55762,87063,08067,95267,09867,98467,49268,40760,87855,93459,74161,62759,14663,21062,83763,67564,30565,355
  Current Assets6.2%14,28713,45614,44313,55413,17512,62914,77213,99113,92513,27815,99630,92624,64326,95030,29628,36133,72734,02435,83634,91832,728
    Cash Equivalents15.6%5,7044,9365,4124,6994,7394,2965,3384,3624,8934,0655,99712,8866,74610,05111,6319,47411,24016,92717,94014,56913,234
  Inventory3.6%1,6331,5761,5071,4631,4941,4821,6181,6761,7721,7791,6831,0081,052986922882884898814816859
  Net PPE1.1%5,5405,4795,4755,3495,2995,2535,1215,0374,9964,9904,9674,8104,6534,5644,5024,3774,2494,1164,0063,7913,659
  Goodwill0%8,3148,3148,3148,3148,3148,3148,3328,3328,3348,3348,1084,1174,1174,1174,1174,1174,1174,1174,1174,1174,124
  Current Liabilities32.6%13,96410,52811,23710,4239,2208,55811,61010,24510,2149,70511,3979,50910,5648,8799,7599,5678,9619,39710,60510,11610,912
    LT Debt, Non Current-7.6%21,20922,95622,95722,95325,19525,18325,17925,17527,91427,90728,64527,79221,10322,09822,09422,09024,08424,08024,57424,57026,062
Shareholder's Equity1.0%21,15820,93921,24021,08120,21519,91521,06421,47119,71018,96418,22117,47118,14222,17922,65020,73622,75122,09121,53423,00721,734
  Retained Earnings-0.6%15,13815,22315,68715,75615,11714,98616,32416,90315,39214,82114,38113,70914,44518,70919,38817,61619,82919,32619,02420,70619,825
  Additional Paid-In Capital3.7%6,0085,7935,5505,2265,0314,8674,6614,4924,2714,0923,8803,7123,5113,3113,0512,8702,6842,4942,2822,1181,844
Shares Outstanding-0.1%1,2471,2481,2471,2541,2561,2551,2541,2561,2551,2561,2541,2551,2551,2621,2661,2671,2701,2761,2821,2961,298
Minority Interest-10.3%-64.00-58.00-31.00-24.00-21.00-12.00-5.001.007.0012.0019.0026.0011511212513213514014714662.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations6.0%9,5128,9769,0729,71010,10010,61411,38410,0959,0929,3428,1688,8329,2279,0039,1448,9098,4767,7078,4008,8089,290
  Share Based Compensation4.9%7056726376226256266356376396416436396286346366546907688451,004919
Cashflow From Investing-7.9%-2,397-2,222-2,466-2,369-1,890-2,159-3,131-11,830-11,867-16,313-14,615-5,207-6,777-7,917-7,817-5,513-1,6479,75714,3551,604-2,535
Cashflow From Financing-1.6%-6,179-6,081-6,469-6,857-8,266-8,194-8,877-6,804847904770-257-6,896-7,879-7,634-8,408-8,794-8,089-12,318-7,301-2,230
  Dividend Payments0.6%3,7573,7333,7093,6883,6593,6333,6053,5693,5303,4923,4493,3923,3353,2793,2223,1573,0953,0352,9712,9172,857
  Buy Backs5.4%1,5701,4901,3966996546335465415966091,5831,7331,7472,2781,7492,6412,8762,7422,9002,0911,757

GILD Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:    
Total revenues$ 6,599$ 6,260$ 12,951$ 12,850
Costs and expenses:    
Cost of goods sold1,4421,4422,8432,866
Research and development expenses1,4071,1022,8542,280
Acquired in-process research and development expenses236330717338
In-process research and development impairment0002,700
Selling, general and administrative expenses1,8491,3573,1682,440
Total costs and expenses4,9344,2319,58110,624
Operating income1,6652,0293,3702,226
Interest expense(230)(242)(459)(480)
Other income (expense), net152(284)(22)(395)
Income before income taxes1,5881,5032,8881,351
Income tax expense(549)(368)(865)(204)
Net income1,0391,1352,0241,147
Net loss attributable to noncontrolling interest693216
Net income attributable to Gilead$ 1,045$ 1,144$ 2,055$ 1,163
Basic earnings per share attributable to Gilead (in dollars per share)$ 0.84$ 0.91$ 1.65$ 0.93
Shares used in basic earnings per share attributable to Gilead calculation (in shares)1,2491,2561,2491,255
Diluted earnings per share attributable to Gilead (in dollars per share)$ 0.83$ 0.91$ 1.63$ 0.92
Shares used in diluted earnings per share attributable to Gilead calculation (in shares)1,2581,2601,2601,261
Product sales    
Revenues:    
Total revenues$ 6,564$ 6,138$ 12,870$ 12,672
Royalty, contract and other revenues    
Revenues:    
Total revenues$ 35$ 122$ 81$ 178

GILD Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 5,704$ 5,412
Short-term marketable debt securities963973
Accounts receivable, net4,2294,777
Inventories1,6331,507
Prepaid and other current assets1,7571,774
Total current assets14,28714,443
Property, plant and equipment, net5,5405,475
Long-term marketable debt securities1,3341,245
Intangible assets, net27,75028,894
Goodwill8,3148,314
Other long-term assets5,1134,800
Total assets62,33763,171
Current liabilities:  
Accounts payable622905
Accrued rebates3,4943,479
Other current liabilities5,8104,580
Current portion of long-term debt and other obligations, net4,0372,273
Total current liabilities13,96411,237
Long-term debt, net21,20922,957
Long-term income taxes payable2,6103,916
Deferred tax liability2,1062,673
Other long-term obligations1,3541,179
Commitments and contingencies (Note 10)
Stockholders’ equity:  
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding00
Common stock, par value $0.001 per share; 5,600 shares authorized; 1,247 shares issued and outstanding11
Additional paid-in capital6,0085,550
Accumulated other comprehensive income102
Retained earnings15,13815,687
Total Gilead stockholders’ equity21,15821,240
Noncontrolling interest(64)(31)
Total stockholders’ equity21,09421,209
Total liabilities and stockholders’ equity$ 62,337$ 63,171
Daniel P. O'Day
14400
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.